TrueMark Investments LLC Acquires New Shares in Gilead Sciences, Inc. $GILD

TrueMark Investments LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 4,675 shares of the biopharmaceutical company’s stock, valued at approximately $574,000.

Other large investors have also added to or reduced their stakes in the company. Corundum Trust Company INC bought a new stake in shares of Gilead Sciences during the third quarter valued at about $26,000. Howard Hughes Medical Institute bought a new position in shares of Gilead Sciences in the second quarter valued at approximately $30,000. MTM Investment Management LLC boosted its position in shares of Gilead Sciences by 176.0% in the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 176 shares during the period. Kilter Group LLC purchased a new position in Gilead Sciences during the second quarter valued at approximately $33,000. Finally, Board of the Pension Protection Fund purchased a new position in Gilead Sciences during the fourth quarter valued at approximately $37,000. Institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the sale, the chief executive officer owned 642,308 shares in the company, valued at $92,999,775.32. This trade represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $144.23, for a total value of $432,690.00. Following the sale, the insider directly owned 131,779 shares of the company’s stock, valued at approximately $19,006,485.17. This trade represents a 2.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 299,280 shares of company stock worth $42,820,550. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Trading Up 1.6%

Shares of Gilead Sciences stock opened at $136.34 on Tuesday. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The firm has a market cap of $169.23 billion, a PE ratio of 20.14, a PEG ratio of 1.76 and a beta of 0.36. The company has a 50 day simple moving average of $144.32 and a two-hundred day simple moving average of $128.89.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were paid a $0.82 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend was Friday, March 13th. Gilead Sciences’s payout ratio is currently 48.45%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on GILD shares. Bank of America set a $162.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Argus boosted their price target on shares of Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Citigroup reaffirmed a “buy” rating on shares of Gilead Sciences in a report on Friday, March 6th. Sanford C. Bernstein reiterated an “outperform” rating and issued a $160.00 price objective on shares of Gilead Sciences in a research report on Wednesday, February 11th. Finally, Barclays initiated coverage on Gilead Sciences in a research report on Friday, February 20th. They set an “equal weight” rating and a $155.00 target price for the company. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $157.62.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.